/Abbvie%20Inc%20logo%20and%20meds-%20by%20Ascannio%20via%20Shutterstock.jpg)
North Chicago, Illinois-based AbbVie Inc. (ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. With a market cap of $334.3 billion, the company discovers and develops medicines and therapies that solve health issues across immunology, oncology, aesthetics, neuroscience, and eye care. The drug giant is expected to announce its fiscal second-quarter earnings for 2025 before the market opens on Thursday, Jul. 31.
Ahead of the event, analysts expect ABBV to report a profit of $3.24 per share on a diluted basis, up 22.3% from $2.65 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports.
For the full year, analysts expect ABBV to report EPS of $12.28, up 21.3% from $10.12 in fiscal 2024. Its EPS is expected to rise 14.5% year over year to $14.06 in fiscal 2026.
ABBV stock has outperformed the S&P 500 Index’s ($SPX) 13.4% gains over the past 52 weeks, with shares up 15.5% during this period. Similarly, it outperformed the Health Care Select Sector SPDR Fund’s (XLV) 5.4% dip over the same time frame.
ABBV's outperformance is driven by the success of new immunology medicines Skyrizi and Rinvoq, which are offsetting the loss of exclusivity for Humira. Strategic acquisitions, including Capstan Therapeutics and ImmunoGen, are strengthening its pipeline in immunology, oncology, and neuroscience, positioning the company for robust revenue growth in 2025 and beyond. In addition, AbbVie's focus on oncology is gaining traction with new products like Elahere and Epkinly, along with its new drug entry in the obesity market.
On Apr. 25, ABBV shares closed up more than 3% after reporting its Q1 results. Its adjusted EPS of $2.46 surpassed Wall Street expectations of $2.39. The company’s revenue was $13.3 billion, beating Wall Street forecasts of $12.9 billion. ABBV expects full-year adjusted EPS in the range of $12.09 to $12.29.
Analysts’ consensus opinion on ABBV stock is moderately bullish, with a “Moderate Buy” rating overall. Out of 27 analysts covering the stock, 14 advise a “Strong Buy” rating, two suggest a “Moderate Buy,” and 11 give a “Hold.” ABBV’s average analyst price target is $208.88, indicating a potential upside of 10.4% from the current levels.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
